Evidence map›Paper›PMID 37510740›Full record

ReviewJournal of clinical medicine2023

Magnetic Resonance Imaging in Clinical Trials of Diabetic Kidney Disease.

Iris Friedli, Seema Baid-Agrawal, Robert Unwin, Arvid Morell, Lars Johansson, Paul D Hockings

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. One Year at AJKD: A Perspective From the 2023-2024 Editorial Interns.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Iris FriedliAntaros Medical, BioVenture Hub, 43183 Mölndal, Sweden.ORCID 0000-0002-6571-3648
Seema Baid-AgrawalTransplant Center, Sahlgrenska University Hospital, University of Gothenburg, 41345 Gothenburg, Sweden.ORCID 0000-0001-8192-1079
Robert UnwinAstraZeneca R&D BioPharmaceuticals, Translational Science and Experimental Medicine, Early Cardiovascular, Renal & Metabolic Diseases (CVRM), Granta Park, Cambridge CB21 6GH, UK.
Arvid MorellAntaros Medical, BioVenture Hub, 43183 Mölndal, Sweden.
Lars JohanssonAntaros Medical, BioVenture Hub, 43183 Mölndal, Sweden.ORCID 0000-0001-5954-3497
Paul D HockingsAntaros Medical, BioVenture Hub, 43183 Mölndal, Sweden.ORCID 0000-0002-7154-9047
Antaros Medical (Sweden) · SEAstraZeneca (United Kingdom) · GBSahlgrenska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) associated with diabetes mellitus (DM) (known as diabetic kidney disease, DKD) is a serious and growing healthcare problem worldwide. In DM patients, DKD is generally diagnosed based on the presence of albuminuria and a reduced glomerular filtration rate. Diagnosis rarely includes an invasive kidney biopsy, although DKD has some characteristic histological features, and kidney fibrosis and nephron loss cause disease progression that eventually ends in kidney failure. Alternative sensitive and reliable non-invasive biomarkers are needed for DKD (and CKD in general) to improve timely diagnosis and aid disease monitoring without the need for a kidney biopsy. Such biomarkers may also serve as endpoints in clinical trials of new treatments. Non-invasive magnetic resonance imaging (MRI), particularly multiparametric MRI, may achieve these goals. In this article, we review emerging data on MRI techniques and their scientific, clinical, and economic value in DKD/CKD for diagnosis, assessment of disease pathogenesis and progression, and as potential biomarkers for clinical trial use that may also increase our understanding of the efficacy and mode(s) of action of potential DKD therapeutic interventions. We also consider how multi-site MRI studies are conducted and the challenges that should be addressed to increase wider application of MRI in DKD.

Indexed as

chronic kidney diseaseclinical trialsdiabetic kidney diseasekidney failuremagnetic resonance imagingmultiparametric magnetic resonance imagingnon-invasive biomarkerssurrogate endpoints

Identifiers

PMID37510740
PMCPMC10380287
OpenAlexW4384037095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.